156 filings
Page 4 of 8
8-K
dqpux084t
26 Aug 21
Termination of a Material Definitive Agreement
4:15pm
NT 10-Q
klvzkm9q6uyzlq
9 Aug 21
Notice of late quarterly filing
9:31pm
8-K
ggducktyp63dtxx
9 Aug 21
Arcturus Therapeutics Announces Second Quarter 2021 Financial Results and mRNA Vaccine and Therapeutics Pipeline Progress
4:02pm
8-K
r4hu15 0k
4 Aug 21
Entry into a Material Definitive Agreement
4:15pm
8-K
84upjddwru0kr
22 Jun 21
Submission of Matters to a Vote of Security Holders
4:31pm
8-K
b0opvw1d0yit
10 May 21
Arcturus Therapeutics Announces First Quarter 2021 Company Overview and Financial Results and Provides New Clinical Data
4:21pm
8-K
3us9r tz1v7ftmf
26 Apr 21
Departure of Directors or Certain Officers
5:15pm
8-K
cczd 0etprkanannz
1 Mar 21
Arcturus Therapeutics Announces Fourth Quarter and Full Year 2020 Financial Results and Positive Clinical Updates
4:20pm
8-K
h4xg6l e34e
22 Feb 21
Arcturus Therapeutics Acquires Exclusive License to mRNA Manufacturing Technology from Alexion Pharmaceuticals
5:00pm
8-K
jjm4v9ls1iuyfq 0kj8u
3 Feb 21
Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
1:00pm
424B5
jau892r5cbql1avsq
8 Dec 20
Prospectus supplement for primary offering
5:30pm
8-K
l0zf j55iwn5ydc
8 Dec 20
Arcturus Therapeutics Announces Pricing of $150 Million Public Offering of Common Stock
9:01am
424B5
h0efl3 x7z
7 Dec 20
Prospectus supplement for primary offering
5:20pm
S-3ASR
umpc7
7 Dec 20
Automatic shelf registration
4:15pm
8-K
aatvrk8r4kfhqaof wkb
7 Dec 20
Entry into a Material Definitive Agreement
6:02am
8-K
06ki pylg
25 Nov 20
Amendments to Articles of Incorporation or Bylaws
4:49pm